PMC:7408073 / 82862-83276 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T461","span":{"begin":22,"end":25},"obj":"Body_part"},{"id":"T463","span":{"begin":332,"end":336},"obj":"Body_part"},{"id":"T464","span":{"begin":337,"end":349},"obj":"Body_part"}],"attributes":[{"id":"A461","pred":"fma_id","subj":"T461","obj":"http://purl.org/sig/ont/fma/fma13443"},{"id":"A462","pred":"fma_id","subj":"T461","obj":"http://purl.org/sig/ont/fma/fma68615"},{"id":"A463","pred":"fma_id","subj":"T463","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A464","pred":"fma_id","subj":"T464","obj":"http://purl.org/sig/ont/fma/fma62861"}],"text":"specific anti SARS-Co-V-2 therapeutic monoclonal antibodies. Despite the promising data that demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates [174], we cannot be sure to get a vaccine against SARS-CoV-2 (see [175]). Indeed, animals immunized with inactivated SARS-CoV vaccines developed a severe (asthma-like) lung eosinophilic immunopathology when challenged with SARS-CoV, further indicatin"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T159","span":{"begin":332,"end":336},"obj":"Body_part"}],"attributes":[{"id":"A159","pred":"uberon_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"specific anti SARS-Co-V-2 therapeutic monoclonal antibodies. Despite the promising data that demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates [174], we cannot be sure to get a vaccine against SARS-CoV-2 (see [175]). Indeed, animals immunized with inactivated SARS-CoV vaccines developed a severe (asthma-like) lung eosinophilic immunopathology when challenged with SARS-CoV, further indicatin"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2890","span":{"begin":132,"end":142},"obj":"Species"},{"id":"2891","span":{"begin":214,"end":224},"obj":"Species"},{"id":"2892","span":{"begin":281,"end":289},"obj":"Species"},{"id":"2893","span":{"begin":387,"end":395},"obj":"Species"},{"id":"2900","span":{"begin":319,"end":325},"obj":"Disease"}],"attributes":[{"id":"A2890","pred":"tao:has_database_id","subj":"2890","obj":"Tax:2697049"},{"id":"A2891","pred":"tao:has_database_id","subj":"2891","obj":"Tax:2697049"},{"id":"A2892","pred":"tao:has_database_id","subj":"2892","obj":"Tax:694009"},{"id":"A2893","pred":"tao:has_database_id","subj":"2893","obj":"Tax:694009"},{"id":"A2900","pred":"tao:has_database_id","subj":"2900","obj":"MESH:D001249"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"specific anti SARS-Co-V-2 therapeutic monoclonal antibodies. Despite the promising data that demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates [174], we cannot be sure to get a vaccine against SARS-CoV-2 (see [175]). Indeed, animals immunized with inactivated SARS-CoV vaccines developed a severe (asthma-like) lung eosinophilic immunopathology when challenged with SARS-CoV, further indicatin"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T466","span":{"begin":14,"end":18},"obj":"Disease"},{"id":"T467","span":{"begin":132,"end":140},"obj":"Disease"},{"id":"T468","span":{"begin":132,"end":136},"obj":"Disease"},{"id":"T469","span":{"begin":214,"end":222},"obj":"Disease"},{"id":"T470","span":{"begin":214,"end":218},"obj":"Disease"},{"id":"T471","span":{"begin":281,"end":289},"obj":"Disease"},{"id":"T472","span":{"begin":281,"end":285},"obj":"Disease"},{"id":"T473","span":{"begin":319,"end":325},"obj":"Disease"},{"id":"T474","span":{"begin":387,"end":395},"obj":"Disease"},{"id":"T475","span":{"begin":387,"end":391},"obj":"Disease"}],"attributes":[{"id":"A466","pred":"mondo_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A467","pred":"mondo_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A468","pred":"mondo_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A469","pred":"mondo_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A470","pred":"mondo_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A471","pred":"mondo_id","subj":"T471","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A472","pred":"mondo_id","subj":"T472","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A473","pred":"mondo_id","subj":"T473","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A474","pred":"mondo_id","subj":"T474","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A475","pred":"mondo_id","subj":"T475","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"specific anti SARS-Co-V-2 therapeutic monoclonal antibodies. Despite the promising data that demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates [174], we cannot be sure to get a vaccine against SARS-CoV-2 (see [175]). Indeed, animals immunized with inactivated SARS-CoV vaccines developed a severe (asthma-like) lung eosinophilic immunopathology when challenged with SARS-CoV, further indicatin"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T998","span":{"begin":155,"end":163},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9443"},{"id":"T999","span":{"begin":196,"end":197},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1000","span":{"begin":246,"end":253},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"},{"id":"T1001","span":{"begin":309,"end":310},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1002","span":{"begin":332,"end":336},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T1003","span":{"begin":332,"end":336},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"specific anti SARS-Co-V-2 therapeutic monoclonal antibodies. Despite the promising data that demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates [174], we cannot be sure to get a vaccine against SARS-CoV-2 (see [175]). Indeed, animals immunized with inactivated SARS-CoV vaccines developed a severe (asthma-like) lung eosinophilic immunopathology when challenged with SARS-CoV, further indicatin"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T63956","span":{"begin":19,"end":21},"obj":"Chemical"}],"attributes":[{"id":"A96164","pred":"chebi_id","subj":"T63956","obj":"http://purl.obolibrary.org/obo/CHEBI_27638"}],"text":"specific anti SARS-Co-V-2 therapeutic monoclonal antibodies. Despite the promising data that demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates [174], we cannot be sure to get a vaccine against SARS-CoV-2 (see [175]). Indeed, animals immunized with inactivated SARS-CoV vaccines developed a severe (asthma-like) lung eosinophilic immunopathology when challenged with SARS-CoV, further indicatin"}

{"project":"LitCovid-sentences","denotations":[{"id":"T407","span":{"begin":61,"end":237},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"specific anti SARS-Co-V-2 therapeutic monoclonal antibodies. Despite the promising data that demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates [174], we cannot be sure to get a vaccine against SARS-CoV-2 (see [175]). Indeed, animals immunized with inactivated SARS-CoV vaccines developed a severe (asthma-like) lung eosinophilic immunopathology when challenged with SARS-CoV, further indicatin"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T142","span":{"begin":319,"end":325},"obj":"Phenotype"}],"attributes":[{"id":"A142","pred":"hp_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"specific anti SARS-Co-V-2 therapeutic monoclonal antibodies. Despite the promising data that demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates [174], we cannot be sure to get a vaccine against SARS-CoV-2 (see [175]). Indeed, animals immunized with inactivated SARS-CoV vaccines developed a severe (asthma-like) lung eosinophilic immunopathology when challenged with SARS-CoV, further indicatin"}